HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial
Korthuis P, King C, Cook R, Khuyen T, Kunkel L, Bart G, Nguyen T, Thuy D, Bielavitz S, Nguyen D, Tam N, Giang L. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial. The Lancet HIV 2021, 8: e67-e76. PMID: 33539760, PMCID: PMC8082651, DOI: 10.1016/s2352-3018(20)30302-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBuprenorphineCD4 Lymphocyte CountDrug Therapy, CombinationFemaleHIV InfectionsHumansMaleMethadoneMiddle AgedNaloxoneNarcotic AntagonistsNarcoticsOpiate Substitution TreatmentOpioid-Related DisordersPatient ComplianceRandom AllocationRNA, ViralTreatment OutcomeVietnamViral LoadConceptsMethadone maintenance therapyOpioid use disorderHIV viral suppressionMaintenance therapySerious adverse eventsViral suppressionAdverse eventsNon-inferiority trialUse disordersHIV clinicNaloxone treatmentComputer-generated random number sequenceOpioid use disorder medicationsTreatment-emergent adverse eventsHIV clinic visitsQuarterly study visitsBuprenorphine adherenceCD4 countHIV careClinic visitsBuprenorphine treatmentHIV outcomesMiddle-income countriesPrimary outcomeMean age